(Q36729145)

English

Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer.

scientific article published on January 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17280909%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

1 reference

Europe PubMed Central

Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17280909%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

1 reference

based on heuristic

inferred from title

neoadjuvant chemotherapy

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17280909%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17280909%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

1

object named as

Cora N Sternberg

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17280909%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

author name string

Joaquim Bellmunt

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17280909%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

Randall E Millikan

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17280909%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

Walter Stadler

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17280909%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

Pieter De Mulder

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17280909%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

Hans von der Maase

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17280909%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

Taiji Tsukamoto

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17280909%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

Mark S Soloway

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17280909%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

language of work or name

0 references

publication date

1 January 2007

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17280909%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17280909%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

69

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17280909%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

1 Suppl

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17280909%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

62-79

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17280909%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

Cystectomy for bladder cancer: a contemporary series

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

Prognostic factors of outcome after radical cystectomy for bladder cancer: a retrospective study of a homogeneous patient cohort

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

Current perspectives in muscle invasive bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

Can patient selection for bladder preservation be based on response to chemotherapy?

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

Complications of radical cystectomy: impact of the timing of perioperative chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

Neoadjuvant cisplatin-methotrexate chemotherapy for invasive bladder cancer -- Nordic cystectomy trial 2

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

Neo-adjuvant (Pre-emptive) Cisplatin Therapy in Invasive Transitional Cell Carcinoma of the Bladder

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

Alternating chemo-radiotherapy in bladder cancer: A conservative approach

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

Five-year followup of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial I. The Nordic Cooperative Bladder Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

Surgical factors influence bladder cancer outcomes: a cooperative group report

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

Urinary diversion: ileal conduit to neobladder

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

Radical Cystectomy for Carcinoma of the Bladder: 16 Years of Experience

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

The curability if invasive bladder cancer treated by radical cystectomy

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

Total Cystectomy for Bladder Cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

Contemporary cystectomy with pelvic node dissection compared to preoperative radiation therapy plus cystectomy in management of invasive bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

Results of radical cystectomy for primary bladder cancer. Retrospective study of more than 200 cases

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

Long-term patient survival after cystectomy for regional metastatic transitional cell carcinoma of the bladder

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

Results of contemporary radical cystectomy for invasive bladder cancer: a clinicopathological study with an emphasis on the inadequacy of the tumor, nodes and metastases classification

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

A bladder cancer multi-institutional experience with total cystectomy for muscle-invasive bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

Radical cystectomy for bladder cancer today--a homogeneous series without neoadjuvant therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

The value of pathologic factors in predicting cancer-specific survival among patients treated with radical cystectomy for transitional cell carcinoma of the bladder and prostate

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

Radical cystectomy for stages Ta, Tis and T1 transitional cell carcinoma of the bladder.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

Treatment of patients with carcinoma of the bladder

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

The role of conservative surgery in the treatment of bladder tumours

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

Control of Bladder Tumors by Endoscopic Surgery

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

Conservative management of muscle-infiltrating bladder cancer: prospective experience.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

Comparison of transurethral resection to radical therapies for stage B bladder tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

Feasibility of transurethral resection for muscle infiltrating carcinoma of the bladder: long-term followup of a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

Transurethral resection of muscle-invasive bladder cancer: 10-year outcome

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

Uncertainty, stage and outcome of invasive bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

Treatment of invasive bladder cancer by local resection and high dose methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

Neoadjuvant chemotherapy and bladder-sparing surgery for invasive bladder cancer: ten-year outcome

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

Radical transurethral resection and chemotherapy in the treatment of muscle-invasive bladder cancer: a long-term follow-up

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

Primary cisplatin, methotrexate and vinblastine aiming at bladder preservation in invasive bladder cancer: multivariate analysis on prognostic factors

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

Neo-adjuvant chemotherapy and bladder preservation in locally advanced transitional cell carcinoma of the bladder

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

Primary methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy and bladder preservation in locally invasive bladder cancer: a 5-year followup

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

Overview of bladder cancer trials in the Radiation Therapy Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

Combined modality program with possible organ preservation for invasive bladder carcinoma: results of RTOG protocol 85-12

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

Neo-adjuvant and adjuvant chemotherapy of bladder cancer: Is there a role?

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

Advanced Bladder Cancer (Stages pT3b, pT4a, pN1 and pN2): Improved Survival after Radical Cystectomy and 3 Adjuvant Cycles of Chemotherapy. Results of a Controlled Prospective Study

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

Adjuvant cisplatin chemotherapy following cystectomy for bladder cancer: results of a prospective randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

Adjuvant cyclophosphamide, doxorubicin, and cisplatin chemotherapy for bladder cancer: an update

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

The role of adjuvant combination chemotherapy after cystectomy in locally advanced bladder cancer: what we do not know and why.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

Prognostic factors for survival of patients with advanced urothelial tumors treated with methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

A randomized trial of cisplatin versus cisplatin plus methotrexate in advanced cancer of the urothelial tract

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

Combination chemotherapy with cisplatin and methotrexate in advanced transitional cell cancer of the bladder

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

A randomized trial comparing methotrexate and vinblastine (MV) with cisplatin, methotrexate and vinblastine (CMV) in advanced transitional cell carcinoma: results and a report on prognostic factors in a Medical Research Council study. MRC Advanced B

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

Future directions for gemcitabine in the treatment of genitourinary cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

High-risk metastatic urothelial cancer: chances for cure?

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

New drugs and new approaches for the treatment of metastatic urothelial cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

Second-line treatment of advanced transitional cell carcinoma of the urothelial tract

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

Novel gemcitabine-containing triplets in the management of urothelial cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

Metastatic urothelial cancer: evaluation of prognostic factors and change in prognosis during the last twenty years

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

The role of systemic chemotherapy in the management of muscle-invasive bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

Carboplatin, methotrexate, and vinblastine in patients with bladder cancer who were ineligible for cisplatin-based chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

Carboplatin-based chemotherapy for bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

Gemcitabine in transitional cell carcinoma of the urothelium

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

Brief communication: use of the multitargeted antifolate pemetrexed (Alimta) in genitourinary cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

Gemcitabine, paclitaxel, pemetrexed and other newer agents in urothelial and kidney cancers

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: a phase II clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

Long-term survival in phase II trials of gemcitabine plus cisplatin for advanced transitional cell cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

Paclitaxel in advanced urothelial carcinoma: its role in patients with renal insufficiency and as salvage therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

Phase II study of cisplatin and paclitaxel in advanced carcinoma of the urothelium: an Eastern Cooperative Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

Docetaxel (Taxotere): an active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy-pretreated patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

Docetaxel and cisplatin in metastatic urothelial cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

Docetaxel and cisplatin combination chemotherapy in advanced carcinoma of the urothelium: A multicenter phase II study of the Hellenic Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

Phase II multicentre study of docetaxel plus cisplatin in patients with advanced urothelial cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

A feasibility study of carboplatin with fixed dose of gemcitabine in "unfit" patients with advanced bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

Gemcitabine doublets in advanced urothelial cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

Southwest Oncology Group Study of paclitaxel and carboplatin for advanced transitional-cell carcinoma: the importance of survival as a clinical trial end point

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: an active and tolerable outpatient regimen

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

Carboplatin, methotrexate, and vinblastine in the treatment of patients with advanced urothelial cancer. A phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients. A randomized phase II study

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

New drugs and new approaches in metastatic bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

Radical Cystectomy without Radiation Therapy for Carcinoma of the Bladder

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.10.041

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.UROLOGY.2006.10.041

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17280909%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17280909%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36729145&oldid=2186353681"